StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Abrysvo (bivalent RSV vaccine by Quarter

Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Abrysvo (bivalent RSV vaccine: $208M in Q2 2026, up 45.5% from a year earlier.

Latest, Q2 2026
208
Period ended Jun 28, 2026
Change on a year earlier
+45.5%
143 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
12
Documents cited below

Where the Q2 2026 figure comes from

“|| Abrysvo | 208 | 143 | 46% | 43% | 55 | 101 | (46%) | 153 | 42 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAbrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026208+45.5%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026180+37.4%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025481+142.9%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025279-21.6%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025143+155.4%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025131-9.7%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024198-61.6%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024356-5.1%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 202456–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024145–Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023515–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023375–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 20230–Form 10-Q (filed 2024-08-05) ↗
Q1 2023Apr 2, 20230–Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-27) ↗
Q3 2022Oct 2, 20220–Form 10-Q (filed 2023-11-08) ↗

Breakdown

What makes up abrysvo (bivalent RSV vaccine

Cite this data

StockData. (2026). Pfizer Abrysvo (bivalent RSV vaccine ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/abrysvo-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.